Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

1.450 -0.040 (-2.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Telomir Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows ↗
Telomir-1 shows potential in oncology and age-related diseases, with new findings on its role in tumor suppression and chemotherapy toxicity reduction. 
Via Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success in Age-Reversal Science with Telomir-1
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
Via ACCESS Newswire
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Stabilizes Silver(II) for Advanced Medical Applications
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Via ACCESSWIRE
News headline image
Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration ↗
Telomir Pharmaceuticals' Telomir-1 stabilizes Silver(II) for medical use, addressing instability issues in antimicrobial treatments and wound care solutions. 
Via Benzinga
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Promising Preclinical Results for Age-Related Macular Degeneration
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
Via ACCESS Newswire
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Promising Findings for Age-Reversal Therapy
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
Via ACCESSWIRE
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Advances Copper-Binding Drug for Wilson’s Disease and Age-Related Therapies
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
Via ACCESSWIRE
News headline image
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease ↗
Telomir-1 shows potential as a treatment for Wilson's disease and related disorders, with promising preclinical results and potential for orphan drug designation. 
Via Benzinga
News headline image
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation 
Via News Direct
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Via ACCESSWIRE
News headline image
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday? ↗
Telomir Pharmaceuticals unveils preclinical data on Telomir-1, highlighting its potential in Type 2 diabetes, aging, and inflammatory diseases. 
Via Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Breakthrough Preclinical Results in Type 2 Diabetes Treatment
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
Via ACCESSWIRE
News headline image
Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study
Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study 
Via News Direct
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Success of Telomir-1 in Age-Reversal Science
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Via ACCESSWIRE
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO), Science of Longevity Featured in Upcoming Episode of “Health Uncensored with Dr. Drew”
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Via ACCESSWIRE
News headline image
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs 
Via News Direct
BioMedNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
Via ACCESSWIRE
News headline image
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.